NICE recommends Humira as the first approved treatment for skin condition HD

6 May 2016

UK medicines cost-effectiveness watchdog the National Institute for Health and Care Excellence (NICE) has recommended US pharma major AbbVie’ (NYSE: ABBV) Humira(adalimumab) for the treatment of active moderate to severe hidradenitis suppurativa (HS) in adult patients with an inadequate response to conventional systemic HS therapy, as per the marketing authorization for adalimumab.

This is a change in position following draft guidance in which the NICE Appraisal Committee was minded not to recommend adalimumab and requested further analyses from the company. Following this latest recommendation, suitable patients in England and Wales should be able to access adalimumab on the National Health Service.

Humira is AbbVie’s mega-blockbuster arthritis drug, which has a range of additional indications in other inflammatory conditions and generated sales of over $14 billion in 2015.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK